Principia Wealth Advisory’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.2K Buy
57
+12
+27% +$625 ﹤0.01% 466
2026
Q1
$2.16K Buy
45
+9
+25% +$394 ﹤0.01% 497
2025
Q4
$1.39K Buy
36
+2
+6% +$76 ﹤0.01% 568
2025
Q3
$1.2K Sell
34
-2
-6% -$72 ﹤0.01% 587
2025
Q2
$1.3K Buy
36
+9
+33% +$298 ﹤0.01% 495
2025
Q1
$871 Buy
27
+19
+238% +$602 ﹤0.01% 430
2024
Q4
$204 Buy
+8
New +$212 ﹤0.01% 734

Other funds holding RPRX

Principia Wealth Advisory's RPRX Position: Q2 2026 in Review

Principia Wealth Advisory increased its Royalty Pharma (RPRX) stake by 27% in Q2 2026, buying an estimated $625 and bringing the position to 57 shares worth $3.2K. The position accounts for ﹤0.01% of the portfolio, ranked #466.

Principia Wealth Advisory first reported a position in RPRX in Q4 2024 and has held it in 7 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Principia Wealth Advisory held 57 shares of Royalty Pharma worth $3.2K as of Q2 2026.
  • Principia Wealth Advisory bought 12 Royalty Pharma shares in Q2 2026, an estimated $625.
  • Royalty Pharma made up ﹤0.01% of Principia Wealth Advisory's portfolio in Q2 2026, its #466 holding.
  • Principia Wealth Advisory first reported a position in Royalty Pharma in Q4 2024 and has held it in 7 quarters since.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Principia Wealth Advisory's 13F filing for Q2 2026, filed 26 Aug 2026.